Criteria of evidence to move potential chemopreventive agents into late phase clinical trials

Current Drug Targets

Volumn 12, Issue 13, 2011, Pages 1983-1988

  Kelly, Ronan J ^a   Lopez Chavez, Ariel ^a   Szabo, Eva ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Chemoprevention; Clinical trials

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANETHOLE TRITHIONE; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BCR ABL PROTEIN; BETA CAROTENE; BRCA1 PROTEIN; BRCA2 PROTEIN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; RALOXIFENE; ROFECOXIB; SELENIUM; SULINDAC; SULINDAC SULFONE; TAMOXIFEN;

ADJUVANT THERAPY; ARTHRITIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CANCER REGRESSION; CARCINOGENESIS; CARDIOTOXICITY; CARDIOVASCULAR RISK; CELL GROWTH; CELL SURVIVAL; CEREBROVASCULAR DISEASE; CHEMOPROPHYLAXIS; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COLON CANCER; COLON POLYPOSIS; COLORECTAL ADENOMA; DEEP VEIN THROMBOSIS; DNA DAMAGE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENDOMETRIUM CANCER; EXON; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; LOW DRUG DOSE; LUNG CANCER; LUNG DYSPLASIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE; OSTEOPOROSIS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRECANCER; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIGNAL TRANSDUCTION; SKIN CANCER; STROKE; TREATMENT RESPONSE;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 82055197121     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798184173     Document Type: Article

References (46)

1. Weinstein IB. Addiction to oncogenes-the Achilles heal of cancer. Science 2002; 297: 63-4.
2. Blanke CD, Corless CL. State-of-the art therapy for gastrointestinal stromal tumors. Cancer Invest 2005; 23: 274-80.
3. Cohen MH. U.S. Food and Drug Administration drug approval summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005; 11: 12-9.
4. Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trial of imatinib (STI571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005; 16: 1811-6.
5. Burger H, den Bakker MA, Stoter G, Verweij J, Nooter K. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 2003; 39: 793-9.
6. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology 2010; 11(2): 121-8.
7. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or Carboplatin- Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med 2009: a0810699.
8. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-6.
9. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997; 57: 2909-15.
10. Wick M, Hurteau G, Dessev C, et al. Peroxisome proliferatoractivated receptor-gamma is a target of nonsteroidal antiinflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 2002; 62: 1207-14.
11. Corpet DE, Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and metaanalysis of colon chemoprevention in rats, mice and men. Eur J Cancer 2005; 41: 1911-22.
12. Green JE, Hudson T. The promise of genetically engineered mice for cancer prevention studies. Nature reviews 2005; 5: 184-98.
13. Hursting SD, Nunez NP, Patel AC, et al. The utility of genetically altered mouse models for nutrition and cancer chemoprevention research. Mutat Res 2005; 576: 80-92.
14. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 2000; 60: 5040-4.
15. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
16. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885-95.
17. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-84.
18. Anderson WF, Umar A, Hawk ET. Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin Pharmacother 2003; 4: 2193-204.
19. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal cancer. Gastroenterology 2006; 131: 1674-82.
20. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-9.
21. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-90.
22. Meyskens FL, Szabo E. Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev 2005; 14: 1366-9.
23. Guarnieri S, Riso P, Porrini M. Orange juice vs. vitamin C: effect on hydrogen peroxide-induced DNA damage in mononuclear blood cells. Br J Nutr 2007; 97: 639-43.
24. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with nodenegative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479-84.
25. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial: multiple outcomes of raloxifene evaluation. JAMA 1999; 281: 2189-97.
26. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 190: 1371-88.
27. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 2006; 295: 2727-41.
28. Klein EA, Thompson IM, Lippman SM, et al. SELECT: the selenium and vitamin E cancer prevention trial. Urol Oncol 2003; 21: 59-65.
29. Lippman SM, Klein EA, Goodman PJ et al. Effect of selenium and vitamin I on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2008; 301: 39-51.
30. Lam S, MacAulay C, Le Riche JC, et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002; 94(13): 1001-9.
31. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010; 28: 4120-8.
32. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352(11): 1092-102.
33. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Eng J Med 2005; 352: 1071-80.
34. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Eng J Med 2006; 355: 873-884
35. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Eng J Med 2006; 355: 885-95
36. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330(15): 1029-35.
37. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334(18): 1150-5.
38. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-86.
39. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003; 95: 470-8.
40. Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007; 99: 715-26.
41. Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast-cancer risk models. N Eng J Med 2010; 362: 986-93.
42. Lam S, le Riche JC, McWilliams A, et al. A randomized phase IIb trial of Pulmicort turbuhaler (budesonide) in persons with dysplasia of the bronchial epithelium. Clin Cancer Res. 2004; 10: 6502-11
43. Rudin CM, Cohen EEW, Papadimitrakopoulou V, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003; 21: 4546-52.
44. Meyskens FL Jr, McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008; 1: 32-8.
45. Lubet RA, Szabo E, Christov K, et al. Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes. Mol Cancer Ther 2008; 7: 972-9.
46. Hamburg MA, Collins FS. The path to personalized medicine. N Eng J Med 2010; 363: 301-4.